NEKTAR THERAPEUTICS (NKTR) Stock Profile — Insider Trades & Financials

Revenue$21.8M

Net Income-$36.1M

EPS$-8.14

Market Cap$2.2B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Howard Robin

CEO & Executive Director

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.

Founded: 1990
Employees: 137
Headquarters: SAN FRANCISCO, CA, United States

⚡

Core Efficiency

ROE?

-40.16%

ROA?

-12.87%

D/E Ratio?

2.12

Op. Margin?

-126.86%

📊

Profitability Ratios

Net Margin?

-165.45%

Loading company sections...

NEKTAR THERAPEUTICS

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness